› Forums › General Melanoma Community › MEK inhibitor nears approval
- This topic has 27 replies, 4 voices, and was last updated 11 years, 3 months ago by NYKaren.
- Post
-
- January 10, 2013 at 11:15 pm
- Replies
-
-
- January 11, 2013 at 3:01 am
I wonder what “could be close to reaching the market” really means. Anyone hear anything more specific?-
- January 12, 2013 at 3:09 pm
Probably only the FDA knows the answer to your question. It apparently is in the process of approval, however long that might take.
Here is a link that gives info on the process:
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm
And here is another report on the application, which gives contact info for the maker of the drug:
August 07, 2012 NDAs Submitted for Dabrafenib and Trametinib for Unresectable or Metastatic Melanoma
GlaxoSmithKline announced that it has submitted New Drug Applications (NDAs) for dabrafenib and trametinib to the FDA, seeking approval for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation as detected by an FDA-approved test.
GlaxoSmithKline entered a collaboration with bioMérieux in 2010 to develop a molecular theranostic test to detect BRAF V600 (V600E and V600K) gene mutations found in several cancers, including melanoma. bioMérieux has filed for FDA Pre-Market Approval of the test and it is currently being utilized in the Phase 3 trametinib-dabrafenib combination program to identify appropriate patients.
Dabrafenib is a BRAF inhibitor. Trametinib is an MEK inhibitor.
For more information call (888) 825 5249 or visit http://www.gsk.com.
-
- January 12, 2013 at 3:18 pm
I found this on the GSK website, which was interesting because of the opthomologic and cardiac problems reported from the clinical trial on the drug. Wondering if this info will be available to patients or only to researchers, and whether it applies only in the UK, since it was a British medical journal decision about transparency?
-
- January 12, 2013 at 3:18 pm
I found this on the GSK website, which was interesting because of the opthomologic and cardiac problems reported from the clinical trial on the drug. Wondering if this info will be available to patients or only to researchers, and whether it applies only in the UK, since it was a British medical journal decision about transparency?
-
- January 12, 2013 at 3:18 pm
I found this on the GSK website, which was interesting because of the opthomologic and cardiac problems reported from the clinical trial on the drug. Wondering if this info will be available to patients or only to researchers, and whether it applies only in the UK, since it was a British medical journal decision about transparency?
-
- January 12, 2013 at 3:09 pm
Probably only the FDA knows the answer to your question. It apparently is in the process of approval, however long that might take.
Here is a link that gives info on the process:
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm
And here is another report on the application, which gives contact info for the maker of the drug:
August 07, 2012 NDAs Submitted for Dabrafenib and Trametinib for Unresectable or Metastatic Melanoma
GlaxoSmithKline announced that it has submitted New Drug Applications (NDAs) for dabrafenib and trametinib to the FDA, seeking approval for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation as detected by an FDA-approved test.
GlaxoSmithKline entered a collaboration with bioMérieux in 2010 to develop a molecular theranostic test to detect BRAF V600 (V600E and V600K) gene mutations found in several cancers, including melanoma. bioMérieux has filed for FDA Pre-Market Approval of the test and it is currently being utilized in the Phase 3 trametinib-dabrafenib combination program to identify appropriate patients.
Dabrafenib is a BRAF inhibitor. Trametinib is an MEK inhibitor.
For more information call (888) 825 5249 or visit http://www.gsk.com.
-
- January 12, 2013 at 3:09 pm
Probably only the FDA knows the answer to your question. It apparently is in the process of approval, however long that might take.
Here is a link that gives info on the process:
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm
And here is another report on the application, which gives contact info for the maker of the drug:
August 07, 2012 NDAs Submitted for Dabrafenib and Trametinib for Unresectable or Metastatic Melanoma
GlaxoSmithKline announced that it has submitted New Drug Applications (NDAs) for dabrafenib and trametinib to the FDA, seeking approval for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation as detected by an FDA-approved test.
GlaxoSmithKline entered a collaboration with bioMérieux in 2010 to develop a molecular theranostic test to detect BRAF V600 (V600E and V600K) gene mutations found in several cancers, including melanoma. bioMérieux has filed for FDA Pre-Market Approval of the test and it is currently being utilized in the Phase 3 trametinib-dabrafenib combination program to identify appropriate patients.
Dabrafenib is a BRAF inhibitor. Trametinib is an MEK inhibitor.
For more information call (888) 825 5249 or visit http://www.gsk.com.
-
- January 15, 2013 at 11:46 pm
I have been taking the MEK inhibitor, with the BRAF inhibitor for over two years, and i would not say “it is loaded with side affects.” I say it is wonderful, with a few mild side affects, and many of my cohorts feel the same way. -
- January 15, 2013 at 11:46 pm
I have been taking the MEK inhibitor, with the BRAF inhibitor for over two years, and i would not say “it is loaded with side affects.” I say it is wonderful, with a few mild side affects, and many of my cohorts feel the same way. -
- January 15, 2013 at 11:46 pm
I have been taking the MEK inhibitor, with the BRAF inhibitor for over two years, and i would not say “it is loaded with side affects.” I say it is wonderful, with a few mild side affects, and many of my cohorts feel the same way.
-
- January 13, 2013 at 1:48 am
My husband has been on a clinical trial for the GSK MEK inhibitor for 2 1/2 years. His doctor said that he got notice from GSK that it would be on the market this spring.
Pat
-
- January 13, 2013 at 1:48 am
My husband has been on a clinical trial for the GSK MEK inhibitor for 2 1/2 years. His doctor said that he got notice from GSK that it would be on the market this spring.
Pat
-
- January 13, 2013 at 1:48 am
My husband has been on a clinical trial for the GSK MEK inhibitor for 2 1/2 years. His doctor said that he got notice from GSK that it would be on the market this spring.
Pat
- You must be logged in to reply to this topic.